Volume 26, Number 4—April 2020
Synopsis
Severe Fever with Thrombocytopenia Syndrome, Japan, 2013–2017
Table 1
Characteristic |
No. (%) |
p value† | |||
---|---|---|---|---|---|
All case-patients, n = 133 | Nonsurvivors, n = 36 | Survivors, n = 97 | |||
Sex | |||||
M | 63 (47) | 17 (47) | 46 (47) | 0.984 | |
F |
70 (53) |
19 (53) |
51 (53) |
||
Median age, y (IQR) |
73 (65–82) |
78 (68.25–84.75) |
72 (63.5–80) |
0.015‡ |
|
Underlying conditions | |||||
Malignant tumor | 9 (7) | 6 (17) | 3 (3) | 0.006 | |
Diabetes mellitus | 27 (20) | 7 (19) | 12 (12) | 0.860 | |
Hypertension | 47 (35) | 14 (39) | 33 (34) | 0.707 | |
Dyslipidemia | 15 (11) | 3 (8) | 12 (12) | 0.381 | |
None |
36 (27) | 8 (22) | 28 (29) | 0.444 |
*Values are no. (%) unless indicated. IQR, interquartile range.
†Pearson χ2 test used for all variables except age.
‡Wilcoxon rank-sum test.
1Current affiliation: Saitama Prefectural Government, Saitama, Japan.
2Current affiliation: Okayama University of Science, Ehime, Japan.
3Current affiliation: Toyama Institute of Health, Toyama, Japan.
4Group members are listed at the end of the article.
Page created: March 17, 2020
Page updated: August 10, 2020
Page reviewed: August 10, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.